The Europe-wide Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) study has officially ended its formal operation. Along the course of six years, the collaboration has significantly contributed to a better understanding of how amyloid positron emission tomography (PET) can improve the diagnosis and treatment of Alzheimer's disease. In total, nearly 3,600 amyloid PET scans have been collected. AMYPAD’s last General Assembly took place during the 22nd and 23rd of September in Amsterdam, where the attendants had the opportunity to discuss the latest results as well as discussing future activities.
A total of 17 European institutions, including the Barcelonaβeta Brain Research Center (BBRC), pharmaceutical companies and patient associations have participated in the AMYPAD project. Within AMYPAD, two clinical trials have been successfully completed. One the one hand, the Diagnostic and Prognostic Study (DPMS) acquired over 860 scans to study the impact of amyloid PET in improving the diagnostic certainty in memory clinic populations. On the other, the Prognostic and Natural History study (PNHS) conducted 2,700 scans to disease progression and improve risk stratification.
Additional collaborations with other ten parent cohorts have yielded 1,300 images to contribute to the PNHS body of images. The analysis of this extensive database, which will be publicly accessible, will continue after the project completion to advance research against Alzheimer's and other neurodegenerative diseases.
The main outcomes of the project, including scientific publications, posters, software, and communications, can be reviewed on its website. AMYPAD is mainly sponsored by the European Union’s Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking. A list of partners is available here.